|
|
Volumn 14, Issue 10, 2015, Pages 675-676
|
|
The Alzheimer disease market
a
a
a
IQVIA
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
5,6 DIHYDRO 2 IMINO 3 METHYL 6 [4 [5 (1 PROPYNYL) 3 PYRIDINYL] 2 THIENYL] 4 PYRIMIDINONE;
ACI 24;
ADUCANUMAB;
ADVANCED GLYCATION END PRODUCT RECEPTOR;
ALZHEIMER DISEASE VACCINE;
AMYLOID BETA PROTEIN;
AMYLOID PRECURSOR PROTEIN;
AZD 3293;
AZELIRAGON;
BETA SECRETASE 1;
CRENEZUMAB;
E 2609;
GANTENERUMAB;
JNJ 54861911;
MELATONIN;
MONOCLONAL ANTIBODY;
RESVERATROL;
UNCLASSIFIED DRUG;
ASPARTIC PROTEINASE;
BACE1 PROTEIN, HUMAN;
SECRETASE;
ALZHEIMER DISEASE;
AMYLOID NEUROPATHY;
CLINICAL DEMENTIA RATING;
CLINICAL TRIAL (TOPIC);
COGNITIVE DEFECT;
DIET SUPPLEMENTATION;
DISEASE COURSE;
DISEASE SEVERITY;
DRUG DEVELOPMENT;
DRUG EFFICACY;
DRUG INDICATION;
DRUG MARKETING;
DRUG MECHANISM;
DRUG RESEARCH;
GENE MUTATION;
IMMUNOTHERAPY;
MINI MENTAL STATE EXAMINATION;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROTEIN CLEAVAGE;
SHORT SURVEY;
ANTAGONISTS AND INHIBITORS;
HUMAN;
ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR;
ALZHEIMER DISEASE;
AMYLOID PRECURSOR PROTEIN SECRETASES;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ASPARTIC ACID ENDOPEPTIDASES;
DRUG DISCOVERY;
HUMANS;
|
|
EID: 84942991284
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4749 Document Type: Short Survey |
|
Times cited : (47)
|
|
References (2)
|
